Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
What changed

HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)

What changed: HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)

Cancer page →

Every dated change on the records linked to HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Trial result10Milestone8This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordHPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 3

2025Trial resultKEYNOTE-689
KEYNOTE-689 reported
Median EFS 59.
2025Trial resultNIVOPOSTOP (GORTEC 2018-01)
NIVOPOSTOP (GORTEC 2018-01) reported
Three-year disease-free survival 63.
2025MilestoneKEYNOTE-689
KEYNOTE-689 approval and NIVOPOSTOP: immunotherapy around surgery
A milestone in how this cancer is treated.

2024 · 2

2024Trial resultTrilynX
TrilynX reported
EFS 19.
2024MilestoneTrilynX
TrilynX stopped: xevinapant worsens outcomes
A milestone in how this cancer is treated.

2023 · 1

2023Trial resultLow-dose nivolumab plus metronomic chemotherapy (Tata Memorial)
Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial) reported
1-year OS 43.

2022 · 1

2022Trial resultKEYNOTE-412
KEYNOTE-412 reported
Pembrolizumab added to chemoradiotherapy did not significantly improve event-free survival.

2020 · 3

2020Trial resultJAVELIN Head and Neck 100
JAVELIN Head and Neck 100 reported
PFS HR 1.
2020Trial resultOral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)
Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) reported
Median OS 7.
2020MilestoneJAVELIN Head and Neck 100
JAVELIN Head and Neck 100: PD-L1 blockade with chemoradiation fails
A milestone in how this cancer is treated.

2019 · 2

2019Trial resultKEYNOTE-048
KEYNOTE-048 reported
OS 14.
2019MilestoneKEYNOTE-048
KEYNOTE-048: pembrolizumab first line in recurrent disease
A milestone in how this cancer is treated.

2009 · 1

2009MilestoneHPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
MACH-NC update: concomitant chemotherapy adds about 6.5 points to five-year survival
A milestone in how this cancer is treated.

2008 · 2

2008Trial resultEXTREME
EXTREME reported
OS 10.
2008MilestoneEXTREME
EXTREME: cetuximab with platinum-fluorouracil first line
A milestone in how this cancer is treated.

2006 · 2

2006Trial resultBonner trial (cetuximab plus radiotherapy)
Bonner trial (cetuximab plus radiotherapy) reported
Median overall survival 49.
2006MilestoneBonner trial (cetuximab plus radiotherapy)
Cetuximab with radiotherapy improves survival (Bonner)
A milestone in how this cancer is treated.

2004 · 1

2004MilestoneHPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
Bernier and Cooper trials: postoperative cisplatin chemoradiation for extranodal extension or positive margins
A milestone in how this cancer is treated.